Spyre Therapeutics, Inc.SYRENASDAQ
Loading
EV/EBITDA Over TimeContracting
Percentile Rank0
Studio
Year-over-Year Change

Enterprise value to EBITDA ratio

Percentile
P0
Near historical low
vs 2Y Ago
-169.3x
Contraction
Streak
2 yr
Consecutive declineContracting
PeriodValueYoY Change
2025-53.69-1010.5%
2024-4.83-1624.3%
20230.32+441.4%
2022-0.09+98.0%
2021-4.72-11.5%
2020-4.23-42.4%
2019-2.97-0.6%
2018-2.96-17.4%
2017-2.52-1163.2%
20160.24-